Approach

Summary

Licensing status

Publication and contact information

Markers

Fibroblast growth factor receptor (FGFR) fusions associated with multiple cancer types

Patient sample and mouse studies identified FGFR fusions in multiple cancers and suggest inhibiting such targets could have therapeutic benefit. Activating mutations and amplifications of FGFR have previously been identified as drivers in many cancers. In multiple cancer types including bladder, breast and prostate cancer, rearrangements in FGFR were identified. In xenograft mice with bladder cancer cells carrying FGFR3 (CD333) fusions, a small molecule FGFR inhibitor decreased tumor growth compared with vehicle. Next steps could include screening additional cancers for FGFR fusions.
At least six selective FGFR inhibitors are in Phase II testing or earlier to treat various cancers.

SciBX 6(16); doi:10.1038/scibx.2013.404
Published online April 25, 2013

Patent and licensing status unavailable

Wu, Y.-M. et al. Cancer Discov.; published online April 4, 2013;
doi:10.1158/2159-8290.CD-13-0050
Contact: Arul M. Chinnaiyan, University of Michigan, Ann Arbor, Mich.
e-mail:
arul@umich.edu